Venture
Parabilis Medicines, Inc.
Latest Form D 2022-12-02- CIK 1657677
- State MA
- Pharmaceuticals
- 5 Form D offerings since 2015-11-13
- Total sold
- $278M
- across 5 offerings
- Rounds
- 5
- Form D offerings since 2015-11-13
- Latest round
- $178M
- 2022-12-02 · 021-466472
- Investors
- 24
- on the latest round
Connected
named in its Form D filingsOfferings · since 2015-11-135 Form D offeringsExemptions506(b)People · Item 3Gregory L. Verdine + 7 moreInvestors · dashboard1 inferred investor
Parabilis Medicines, Inc.CIK 1657677
Round timeline
amount sold · by first filed2022-12-02 · $178M
- 2015-11-13$625K021-251210
- 2016-06-07$11M021-264481
- 2018-02-14$65.5M021-305650
- 2021-01-05$23.3M021-385216
- 2022-12-02$178M021-466472
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($178M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-466472 | First filed2022-12-02 | Latest2022-12-02 | Sought$178M | Sold$178M | Investors24 | Exemptions506(b) |
| 021-385216 | First filed2021-01-05 | Latest2021-01-05 | Sought$107M | Sold$23.3M | Investors22 | Exemptions506(b) |
| 021-305650 | First filed2018-02-14 | Latest2018-05-16 | Sought$66M | Sold$65.5M | Investors24 | Exemptions506(b) |
| 021-264481 | First filed2016-06-07 | Latest2017-08-22 | Sought$11M | Sold$11M | Investors13 | Exemptions506(b) |
| 021-251210 | First filed2015-11-13 | Latest2015-11-13 | SoughtIndefinite | Sold$625K | Investors4 | Exemptions506(b) |
Who backs Parabilis Medicines, Inc. — 1 inferred investor — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2022-12-02
| Name | Relationship |
|---|---|
| Gregory L. Verdine | RelationshipExecutive Officer, Director |
| Jeffrey A. Leerink | RelationshipDirector |
| Edward M. Fitzgerald | RelationshipDirector |
| WeiQing Zhou | RelationshipExecutive Officer |
| Krishna Yeshwant | RelationshipDirector |
| Barbara Weber | RelationshipDirector |
| Rick Klausner | RelationshipDirector |
| Corey S. Goodman | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Pharmaceuticals
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2015-11-13
- Latest filing
- 2022-12-02
Who backs Parabilis Medicines, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗